Alexion
WEBAt Alexion, AstraZeneca Rare Disease, we are committed to working with the patient community and health care stakeholders worldwide to address the challenges facing the rare disease community. Together, on Rare Disease Day — and every day — we can make a powerful difference.
Acquisition of Alexion completed - AstraZeneca
WEBJul 21, 2021 · AstraZeneca today completed the acquisition of Alexion Pharmaceuticals, Inc. (Alexion). The closing of the acquisition marks the Company’s entry into medicines for rare diseases and the beginning of a new chapter for AstraZeneca.
AstraZeneca to acquire Alexion, accelerating the Company's …
WEBDec 12, 2020 · Alexion's leading expertise in complement biology will accelerate AstraZeneca's growing presence in immunology. The acquisition adds a new technology platform to AstraZeneca's science and innovation-driven strategy. The complement cascade is pivotal to the innate immune system.
Alexion, AstraZeneca Rare Disease, enters agreement with Pfizer …
WEBJul 28, 2023 · Alexion, AstraZeneca Rare Disease, today announced that it has entered a definitive purchase and licence agreement for a portfolio of preclinical gene therapy programmes and enabling technologies from Pfizer Inc. (Pfizer).
AstraZeneca to Buy Alexion for $39 Billion - The New York Times
WEBDec 12, 2020 · LONDON — The drug maker AstraZeneca agreed on Saturday to buy Alexion, a biopharmaceutical company, for $39 billion in cash and stock, as corporate giants resume big-ticket takeovers, even amid...
AstraZeneca to buy Alexion in $39bn immunology deal - Financial Times
WEBDec 12, 2020 · Anglo-Swedish drugmaker AstraZeneca has agreed to buy US biotechnology group Alexion in a $39bn deal, marking the biggest agreement struck by a pharmaceutical company since the start of the...
Alexion, AstraZeneca Rare Disease, Completes Acquisition of …
WEBNov 16, 2022 · LogicBio acquisition to build on current collaborations and advancements in genomic medicine. Alexion, AstraZeneca Rare Disease, today announced the completion of its acquisition of LogicBio® Therapeutics, Inc. (NASDAQ: LOGC), a pioneering genomic medicine company.
Alexion Shareholders Approve Acquisition by AstraZeneca
WEBMay 11, 2021 · BOSTON -- (BUSINESS WIRE)-- Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that its shareholders have voted to adopt and approve the previously announced agreement to be acquired by...
Alexion, AstraZeneca Rare Disease to Acquire LogicBio® …
WEBOct 3, 2022 · Alexion, AstraZeneca Rare Disease, today announced that it has entered a definitive agreement to acquire Lexington, Mass.-based LogicBio® Therapeutics, Inc. (NASDAQ: LOGC), a pioneering genomic medicine company.
AstraZeneca concludes Alexion acquisition for $39bn
WEBJul 22, 2021 · AstraZeneca has concluded the acquisition of US-based biopharmaceutical company Alexion Pharmaceuticals for a total consideration of $39bn or $175 per share.
- Some results have been removed
Skip to content